How much muscle are you losing on GLP-1? 2026 trial data

How much muscle are you losing on GLP-1? 2026 trial data

Forty percent. In the DXA sub-study of STEP 1, that is the share of body-weight loss that came from lean mass, not fat. The headline everyone remembers from that trial is the 14.9% reduction in body weight at 68 weeks. The number underneath it rarely makes the press release.

Tirzepatide runs a different ratio. SURMOUNT-1 enrolled 2,539 adults and posted 20.9% weight loss at 72 weeks on the 15 mg dose, with a fat-to-lean loss ratio near 3 to 1, which puts lean mass at roughly 25% of the total. Lower than semaglutide, but still not a number you can ignore.

If you are on Wegovy, Zepbound, Mounjaro, Ozempic, or Saxenda, the muscle question is the one your bathroom scale will not answer. What follows is what the trials actually show, who is most exposed, and the protein-and-resistance protocol the obesity-medicine community has settled on as of April 2026.

How much of your lost weight is muscle

Three numbers, three sources, no spin.

Wilding et al. published STEP 1 in NEJM in 2021. The DXA sub-study reported a 19.3% drop in fat mass and a 10.4% drop in lean mass. Do the arithmetic against total weight change and lean tissue accounts for roughly 40% of the loss. That is higher than anyone anticipated when semaglutide 2.4 mg first hit the market.

Jastreboff et al. published SURMOUNT-1 in NEJM in 2022. Tirzepatide 15 mg produced that 3:1 fat-to-lean ratio, bringing lean-mass share down to about 25%. Why the gap? Dual GIP plus GLP-1 agonism probably explains most of it, with some contribution from differences in appetite pattern and maybe a direct effect on protein synthesis. The mechanism is not fully worked out. The clinical ratio, though, reproduces across the SURMOUNT program.

The third source is the Harvard Science Review piece from February 23, 2026, "The GLP-1 Aftermath — muscle loss and cellular aging." It puts both numbers in context. Any rapid weight loss, even straight caloric restriction, costs roughly 25% lean mass as a floor. GLP-1s sit in a 25% to 40% band depending on the molecule. The clinically useful question is not whether you lose lean mass on these drugs. You do. It is whether you lose enough to affect grip strength, gait speed, or the ability to climb a flight of stairs at 70.

Lean mass is not cosmetic tissue. It drives insulin sensitivity, fall risk, and how easily you recover from a hospital stay. On a GLP-1, you can lose a meaningful amount of it without noticing until a specific task — carrying a full laundry basket up the stairs, opening a jar — gets harder.

Trial-by-trial: what the DXA sub-studies showed

Cleanest side-by-side from the published evidence. The lean-mass share column is the fraction of total weight loss that came from non-fat tissue.

A few things worth reading from that grid. STEP 5 ran two years and the weight loss held, but the muscle curve does not flatten on its own. It keeps ticking unless you intervene. Retatrutide, Lilly's triple agonist, posted the largest weight loss on record, yet its lean-mass share looks like the lowest of the bunch in the data available so far. The bimagrumab combination, reported by Heymsfield et al. in JAMA in 2024, is the first credible signal that muscle can be pharmacologically protected during GLP-1 weight loss. It is in Phase 3 now. Worth watching, not worth prescribing.

One more line that matters: STEP 4 (Rubino et al., JAMA 2021). When patients stopped semaglutide after a 20-week run-in, about two-thirds of the weight came back within a year. Fat returned faster than muscle. Stop without a maintenance plan that includes resistance training, and your body composition can land worse than baseline at the same scale weight.

Why tirzepatide and semaglutide land differently on lean mass

The simple read: tirzepatide hits two receptors, semaglutide hits one. GIP signaling appears to act on adipose tissue in a way that GLP-1 alone does not, which probably explains the more favorable fat-to-lean ratio.

The honest read: no one has a clean mechanistic answer. The clinical pattern is real and reproducible. The "why" still lives in animal models, mitochondrial biopsies, and small substudies that have not been pooled into a meta-analysis worth quoting.

What you can act on today is the pattern itself. If protecting lean mass matters to you and your insurance gives you a real choice between Wegovy and Zepbound, the trial evidence tilts toward tirzepatide on this specific question. That is not a call to switch on your own. It is a data point to put on the table at the next visit.

One more wrinkle: speed. The faster the weight comes off in the first 16 weeks, the higher the lean-mass fraction tends to run. Interestingly, SURMOUNT-1 patients lost weight faster than STEP 1 patients and still showed a lower lean-mass share, so pace alone does not predict muscle loss. Molecule and titration both factor in.

Which trial is your actual label based on?

This is the part most US patients miss. The drug in your fridge maps to a specific brand, which maps to a specific trial, which maps to a specific lean-mass dataset.

A few US-specific footnotes. Wegovy's 2024 label expansion for cardiovascular risk reduction in adults with established CVD did not move the muscle-loss data. It broadened who qualifies for coverage. Zepbound picked up an OSA indication in late 2024, which opened a new prior-authorization lane. Mounjaro, the same molecule as Zepbound, is still labeled only for type 2 diabetes. If you are taking it off-label for weight, the closest weight-loss evidence is SURMOUNT-1, even though the label cites SURPASS. Foundayo, Eli Lilly's oral orforglipron, cleared the FDA on April 1, 2026, under the ATTAIN-1 and ATTAIN-2 programs.

Outside the US, the map changes fast. In the EU, Mounjaro carries the obesity indication directly, with no separate Zepbound brand. In Korea, tirzepatide sells only as Mounjaro, for diabetes, with obesity use off-label. In Japan, ウゴービ (Wegovy) won conditional reimbursement for BMI 35+ or BMI 27+ with two comorbidities. Mainland China approved 诺和盈 (Wegovy) in June 2024 and extended 穆峰达 (tirzepatide) to obesity in November 2024. The molecule is the same. The access lane is not.

Why this matters for muscle loss: the trial population that generated your label may not look like you. SURMOUNT-1 enrolled adults with a mean BMI near 38. Starting at BMI 28 with already-low lean mass puts you off the median and closer to the top of the lean-mass-share distribution.

Who is most at risk

The risk profile is reasonably well characterized by 2026.

• Adults 65 and older. Sarcopenia risk is already baseline at this age. Adding a GLP-1 without resistance training compounds it.
• Low pre-treatment lean mass. If your baseline DXA already shows a below-normal appendicular lean mass index, you are starting with less reserve.
• Rapid loss, sustained. More than 1% of body weight per week over months costs muscle. Slow it down.
• Protein under 60 g per day. Common once appetite drops 60% in week four. The drug does its job on intake; the protein target is what collapses.
• Sedentary, no resistance training history. Cardio alone does not preserve muscle the way resistance work does.
• Women with limited prior strength training. Not biologically destined to lose more muscle — historically less likely to have been doing the protective work going in.

The lived version of this on r/GLP1 is not subtle.

Down 38 lb in seven months on Zep. Went to help my daughter move last weekend and couldn't carry the boxes I used to. Gym ordered a grip test and I'm down about 18 lb of grip strength since January. Nobody mentioned this part when I started.

This pattern shows up in the medication subs every week. The weight comes off, the strength goes with it, and almost nobody was told at the start to lift.

The 2026 protein and resistance protocol

This is the consensus that has emerged from ESPEN's 2022 obesity pharmacotherapy nutrition guideline, the ISSN's 2024 protein and exercise position stand, and the Academy of Nutrition and Dietetics' 2024 obesity treatment update.

Protein. 1.2 to 1.6 g per kg of body weight per day, split across three meals at 25 to 40 g each. The per-meal threshold matters because muscle protein synthesis plateaus near 0.4 g/kg per meal. Undershoot one meal, and you cannot bank the deficit at the next.

Resistance training. Two to three sessions per week, all major muscle groups. Hold that through the active weight-loss phase, which usually runs 48 to 72 weeks on Wegovy or Zepbound, and keep going into maintenance.

Cardio. Still useful here — 9,000 to 10,000 steps a day appears to protect lean mass on top of resistance work, probably through insulin sensitivity and capillary density.

Hydration. 30 mL per kg per day. For a 70 kg adult, that is about 2.1 liters.

Pace. Target 1 to 2 kg of weight loss per month after the first eight weeks. Faster than that, and the lean-mass share starts creeping up.

Body composition tracking. DXA every three to four months. If DXA is out of budget, segmental bioimpedance (InBody, Tanita) is fine for tracking trends, just not for absolute numbers.

Creatine monohydrate. 3 to 5 g per day, paired with resistance work. Modest signal for lean-mass preservation, and the safety profile is well established.

Protein math gets concrete fast. Here is what 1.2 to 1.6 g per kg looks like by body weight, with the lb-per-day mirror so you can meal-prep in either unit.

Practical notes for the US grocery aisle. A 6 oz chicken breast lands around 38 g. A cup of plain Greek yogurt is 17 to 22 g. A scoop of whey hits 24 g. Two large eggs plus two egg whites is about 19 g. Most patients underestimate by 30 to 40 g per day before they start tracking. One week of measuring is usually enough to recalibrate.

What to ask your doctor — the printable version

Bring these in print, not in your head. The visit is short and the questions are easy to forget once nausea-week-three is the live topic.

• At my current dose, how many resistance sessions per week do you want me doing, and do I need a PT referral?
• If I push protein to 1.4 g per kg, do my kidney numbers stay in range, and how often should we recheck?
• Can we order DXA or segmental bioimpedance every three to four months, and what is realistic on my plan?
• Are any of my other meds working against muscle preservation — corticosteroids, certain antihypertensives, higher-dose statins?
• If my weight is dropping faster than 1.5 kg per month, can we hold the dose for a cycle before escalating?
• Once I reach maintenance, what is the plan for protecting the lean mass I still have?

Arrive with a one-page summary: current weight, protein average for the last week, resistance frequency, and one outcome you want to track. Endocrinology slots are 15 minutes. Let the data do the talking.

Before you pick up the prescription

Five checkpoints worth running through, ideally before the first injection.

• Indication match. BMI 30 or higher, or BMI 27 with at least one weight-related comorbidity. Get this in writing for the prior authorization.
• Molecule and brand clarity. Know whether your prescription is Wegovy, Zepbound, Mounjaro off-label, or Ozempic off-label. Each maps to a different trial dataset and different coverage logic.
• Coverage path. Commercial formulary status, prior-authorization criteria, copay or coinsurance share, step-therapy requirements. Cash-pay backstops include LillyDirect and NovoCare.
• Compounded versus FDA-approved. The compounded landscape narrowed sharply through 2024 and 2025 after the shortage resolved. If your telehealth clinic is still pushing compounded tirzepatide in 2026, ask which 503A or 503B pharmacy is filling and where the active ingredient is sourced.
• Baseline musculoskeletal read. A baseline DXA, a grip-strength reading, and a five-times-sit-to-stand test give you something to compare against six months in. None of this requires a sports-medicine clinic. An obesity-medicine PCP can order it.

A realistic read for US patients

Three anchors worth knowing in spring 2026.

The first is the manufacturer cash-pay lane. LillyDirect lists Zepbound vials starting at $349 per month for the lower doses with auto-refill, scaling to $499 for higher doses. NovoCare runs comparable offers for Wegovy. These are real prices, not lure prices. They sit alongside coverage if you can get it, never instead of it.

The second is Medicare. The GLP-1 coverage bridge begins July 1, 2026, for Wegovy and Zepbound under a narrow obesity-plus-established-cardiovascular-risk indication. The eligible cohort is smaller than the headlines suggested when the rule was finalized in late 2025. If you are 65-plus with documented obesity plus established CVD, have your PCP check whether your chart qualifies under the bridge. The documentation is the bottleneck, not the clinical profile.

The third is the PA appeal pattern, which has stabilized over the last 18 months. Most denials in 2026 hinge on three things: missing BMI documentation in the chart, missing prior trial of a covered alternative (usually metformin or phentermine), and missing comorbidity coding. A clean appeal letter that addresses those three gaps has a meaningful first-re-review approval rate. If your PA gets denied, do not start from scratch. Appeal the existing one with the documentation gap fixed.

The lean-mass conversation lands differently in the US than it does abroad. Mean baseline BMI in the trials runs higher than the median Korean or Japanese patient, which means the lean-mass math may read more conservatively in those markets. In the US, where the median Wegovy patient starts north of BMI 35, the trial numbers translate pretty directly. Your downside is the published downside.

One more thing that does not get said enough: gym access in the US is uneven. A $20-a-month chain gym is fine for protecting lean mass. Squats, presses, rows, and a pull-up bar are not boutique equipment. No gym? A pair of resistance bands and a 30 lb adjustable kettlebell at home gets you 80% of the benefit. The protocol does not require fancy infrastructure. It requires showing up two or three times a week and progressively loading the work.

Raise this at your next endocrinology visit, especially if you are over 60 or starting from a low base of resistance training. The Wegovy or Zepbound side of the conversation usually gets attention. The muscle side often does not. Frame it as "I want to protect my lean mass while we manage the weight," and most prescribers will take it seriously and order the right baselines.

The drug is doing its part. The protein target and the resistance sessions are the part you own.

Start managing your GLP-1 with Blueshot

AI coaching, injection scheduling, and weight tracking in one app